Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 4,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Healthy
Interventions: TAK-831 Tablet T2, Placebo, TAK-831 Suspension; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Interventions: NTX-001 (PEG-Fusion); Combination Product
Lead sponsor: Neuraptive Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 20 more

Conditions: Hypercortisolism
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Stanford, California • Torrance, California + 19 more

Conditions: Refractive Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Idiopathic Scoliosis, Post-operative Pain
Interventions: Ketamine, Placebo; Drug · Other
Lead sponsor: Albany Medical College; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Albany, New York

Conditions: Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Interventions: Dextenza, Topical Prednisolone; Drug
Lead sponsor: Vance Thompson Vision - MT; Other
Eligibility: 22 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: EDP-305, Oral Contraceptive; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pancreatic Cancer
Interventions: Pasireotide (SOM230), placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: mesalamine, ALTH12-1:4, ALTH12-2:4; Drug
Lead sponsor: Altheus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, Vehicle Spray; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more

Conditions: Postoperative Urinary Tract Infection
Interventions: Tamsulosin, Control Group; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Asthma
Interventions: beclomethasone, fluticasone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anthocyanins
Interventions: Plant polyphenol blend, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Davis, California

Conditions: Celiac Disease
Interventions: ALV003, Placebo; Drug
Lead sponsor: Alvine Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: San Diego, California

Conditions: Healthy Volunteer
Interventions: TAK-951, TAK-951 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Ebola Virus Infection
Interventions: TKM-100802 for Injection, Placebo; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obsessive-Compulsive Disorder
Interventions: 3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: Carolyn Rodriguez; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Social Anxiety Disorder, Performance Anxiety
Interventions: BHV-0223, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hyperkalemia
Interventions: Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase), Placebo ( subacute phase); Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Anniston, Alabama • Huntsville, Alabama • Glendale, Arizona + 37 more

Conditions: HIV Infection
Interventions: Polyphenon E, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Healthy Participants
Interventions: REGN10933 + REGN10987, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Day and older
Enrollment: 3,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 132
States / cities: Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more

Conditions: Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Interventions: LINKED-HEARTS Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Denton, Maryland

Conditions: Fragile X Syndrome
Interventions: zatolmilast, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 9 Years to 18 Years · Male only
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Sacramento, California + 14 more

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

The PRIME Study: A Randomized, Controlled, Prospective Study

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

A Study of TAK-951 in Healthy Adults

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome